President Joe Biden will provide an update today on his administration’s response to the Omicron COVID-19 variant; marked rise in lung transplants for patients with COVID-19 sparks ethical questions; an independent panel of experts will advise FDA tomorrow on the use of Merck’s COVID-19 antiviral pill.
As travel restrictions for travelers from several African countries take effect, President Joe Biden is set to provide an update today on his administration’s response to the Omicron COVID-19 variant. As reported by The Hill, it will take roughly 2 weeks to obtain definitive data on the transmissibility and severity threat of the Omicron variant compared with other variants, noted the chief medical advisor to President Biden, Anthony Fauci, MD, during an appearance on ABC’s “This Week.” Labeled a variant of concern by the World Health Organization, Omicron has spread to countries in Africa, Europe, and North America since first being discovered in South Africa.
According to data from the United Network for Organ Sharing, lung transplants in the United States rose 10-fold between the first year of the pandemic and 2021, with approximately 1 in 10 lung transplants performed on patients with COVID-19. As reported by NPR, transplants for other top lung diseases, such as emphysema, cystic fibrosis, and pulmonary fibrosis, were conversely shown to be down compared with prior years, which has raised questions regarding the ethics of allocating these scarce resources to people who elected not to be vaccinated against COVID-19. With more than 2000 lung transplants performed in the United States each year, a double lung transplant costs approximately $1.2 million.
As reported by POLITICO, an independent panel of experts will advise the FDA tomorrow on whether to limit the use of Merck’s COVID-19 antiviral pill for pregnant people due to potential risks. As new data showed the pill, molnupiravir, reduced the risk of hospitalization by 30%, down from a decrease of 50% seen in an earlier analysis, regulators are also considering whether to authorize its emergency use in adults who have been experiencing symptoms for less than 5 days. As pregnant women are an at-risk population for severe COVID-19, the FDA will ask advisers to consider an alternative approach if the pill is deemed unsafe.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More